The Oncologist’s Life

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Results from a phase 2a trial showed a 6-month OS and PFS rate of 94% and 72% compared with 67% and 44% from the phase 3 MPACT trial in the first-line treatment of PDAC.

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

June 16th 2025

Real-World Axicabtagene Ciloleucel Shows Consistent Efficacy, Safety in R/R LBCL

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

$A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.$

Courtney Flaherty

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

CID-078 Earns FDA Orphan Drug Designation in Small Cell Lung Cancer

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early anti-tumor activity of CID-078 in advanced solid tumors.

Roman Fabbricatore

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early anti-tumor activity of CID-078 in advanced solid tumors.

Jax DiEugenio

Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.

Related Content

Tim Cortese

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Results from a phase 2a trial showed a 6-month OS and PFS rate of 94% and 72% compared with 67% and 44% from the phase 3 MPACT trial in the first-line treatment of PDAC.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

June 16th 2025

Real-World Axicabtagene Ciloleucel Shows Consistent Efficacy, Safety in R/R LBCL

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

$A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.$

Courtney Flaherty

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

CID-078 Earns FDA Orphan Drug Designation in Small Cell Lung Cancer

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Roman Fabbricatore

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early anti-tumor activity of CID-078 in advanced solid tumors.

Jax DiEugenio